Nubeqa (darolutamide) received FDA approval for metastatic castration-sensitive prostate cancer, showing significant improvement in radiographic progression-free survival. The ARANOTE trial involved ...
Dr. Rohan Garje shares the updated recommendations for the ASCO guideline on systemic therapy for patients with metastatic castration-resistant prostate cancer. He discusses the systemic therapy ...
MedPage Today on MSN
Recent developments in prostate cancer
Practice-changing perioperative therapy, chemo-free combo for CSPC, reducing cognitive eff ...
Many patients with metastatic castration-resistant prostate cancer are not receiving bone-modifying agents, despite guideline endorsement.
Findings showed darolutamide reduced the risk of radiographic progression or death by 46% compared with placebo. The Food and Drug Administration (FDA) has approved Nubeqa ® (darolutamide), an ...
SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castrate resistant prostate cancer. This is an ASCO Meeting Abstract from ...
The Ellison Medical Institute (EMI) has entered into an exclusive license with UniQuest, the commercialization company of The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results